Iterum Therapeutics Valuation
Is ITRM undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Share Price vs Fair Value
What is the Fair Price of ITRM when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for ITRM?
Other financial metrics that can be useful for relative valuation.
| What is ITRM's n/a Ratio? | |
|---|---|
| n/a | 0x |
| n/a | n/a |
| Market Cap | US$25.95m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | n/a |
| Enterprise Value/EBITDA | -0.5x |
| PEG Ratio | n/a |
Price to Book Ratio vs Peers
How does ITRM's PB Ratio compare to its peers?
| Company | Forward PB | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 4.4x | ||
JAGX Jaguar Health | 9.5x | n/a | US$46.4m |
EYEN Eyenovia | 3.3x | 28.9% | US$27.6m |
QLI Qilian International Holding Group | 0.7x | n/a | US$26.3m |
LEXX Lexaria Bioscience | 4.3x | 22.6% | US$28.9m |
ITRM Iterum Therapeutics | n/a | 50.1% | US$26.0m |
Price to Earnings Ratio vs Industry
How does ITRM's PE Ratio compare vs other companies in the US Pharmaceuticals Industry?
Price to Book Ratio vs Fair Ratio
What is ITRM's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PB Ratio | -4x |
| Fair PB Ratio | n/a |
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?